Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action

A securities fraud class action lawsuit has been filed against ADMA Biologics, Inc. for the Class Period between August 9, 2024 and March 25, 2026. Culper Research alleged the company engaged in channel stuffing and undisclosed related party transactions to artificially inflate revenues. The stock fell 29.1% over two trading days to $9.63 per share following the allegations. Investors have until August 10, 2026 to file a lead plaintiff motion.